IL207641A0 - Compositions comprising nucleic acids encoding vegf antagonists for use in treating ocular disease - Google Patents

Compositions comprising nucleic acids encoding vegf antagonists for use in treating ocular disease

Info

Publication number
IL207641A0
IL207641A0 IL207641A IL20764110A IL207641A0 IL 207641 A0 IL207641 A0 IL 207641A0 IL 207641 A IL207641 A IL 207641A IL 20764110 A IL20764110 A IL 20764110A IL 207641 A0 IL207641 A0 IL 207641A0
Authority
IL
Israel
Prior art keywords
compositions
nucleic acids
acids encoding
ocular disease
treating ocular
Prior art date
Application number
IL207641A
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of IL207641A0 publication Critical patent/IL207641A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL207641A 2008-02-20 2010-08-16 Compositions comprising nucleic acids encoding vegf antagonists for use in treating ocular disease IL207641A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US3007208P 2008-02-20 2008-02-20
US3454608P 2008-03-07 2008-03-07
US5663208P 2008-05-28 2008-05-28
PCT/US2009/034709 WO2009105669A2 (en) 2008-02-20 2009-02-20 Angiogenesis inhibition

Publications (1)

Publication Number Publication Date
IL207641A0 true IL207641A0 (en) 2010-12-30

Family

ID=40986215

Family Applications (1)

Application Number Title Priority Date Filing Date
IL207641A IL207641A0 (en) 2008-02-20 2010-08-16 Compositions comprising nucleic acids encoding vegf antagonists for use in treating ocular disease

Country Status (5)

Country Link
JP (1) JP2011512417A (en)
CN (1) CN101951925A (en)
BR (1) BRPI0908496A2 (en)
IL (1) IL207641A0 (en)
WO (1) WO2009105669A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3357511B1 (en) 2011-06-30 2020-05-13 Genzyme Corporation Inhibitors of t-cell activation
TWI698240B (en) 2012-05-15 2020-07-11 澳大利亞商艾佛蘭屈澳洲私營有限公司 Treatment of amd using aav sflt-1
HUE060464T2 (en) 2013-03-13 2023-03-28 Genzyme Corp Fusion proteins comprising pdgf and vegf binding portions and methods of using thereof
EP3102246B1 (en) * 2014-02-06 2020-03-25 Genzyme Corporation Compositions and methods for treating and preventing macular degeneration
CA2942776C (en) 2014-03-17 2023-01-24 Adverum Biotechnologies, Inc. Polyneucleotide cassette and expression vector for expression of a gene in cone cells using truncated m-opsin promoter
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2016005381A1 (en) * 2014-07-10 2016-01-14 Bayer Pharma Aktiengesellschaft Pdgfrbeta-fc fusion proteins and uses thereof
EA201791939A1 (en) 2015-03-02 2018-01-31 Адверум Байотекнолоджиз, Инк. COMPOSITIONS AND METHODS OF INTRAVITREAL DELIVERY OF POLYNUCLEOTIDES IN RETCHEMBALS
CN108348572B (en) * 2015-03-31 2021-06-29 日东制药株式会社 Pharmaceutical composition for preventing and treating eye diseases comprising fusion protein of fusion tissue penetrating peptide and anti-VEGF preparation
EP3377101A4 (en) * 2015-11-19 2019-08-07 Zhuhai Tairuishang Biopharm Ltd. Methods and compositions for binding vegf
GB2545763A (en) 2015-12-23 2017-06-28 Adverum Biotechnologies Inc Mutant viral capsid libraries and related systems and methods
IL260323B1 (en) 2015-12-30 2024-09-01 Kodiak Sciences Inc Antibodies and conjugates thereof
KR101685532B1 (en) * 2016-04-26 2016-12-13 한국프라임제약주식회사 A VEGFR fusion protein
US12071476B2 (en) 2018-03-02 2024-08-27 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
GB201806333D0 (en) * 2018-04-18 2018-05-30 Glaxosmithkline Ip Dev Ltd Parvovirus vector production
CN108671229B (en) * 2018-05-08 2022-03-25 华博生物医药技术（上海）有限公司 Pharmaceutical composition preparation of recombinant human vascular endothelial growth factor receptor-antibody fusion protein
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
CN114181972A (en) * 2021-11-23 2022-03-15 上海本导基因技术有限公司 Lentiviral vectors suitable for gene therapy of refractory angiogenic eye diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1496944T1 (en) * 2002-05-01 2009-02-28 Univ Florida Improved raav expression systems for genetic modification of specific capsid proteins
BRPI0515264B1 (en) * 2004-09-13 2018-12-18 Genzyme Corp fusion protein according to formula x-y-z, composition, nucleic acid molecule, its uses and multimerization method of a polypeptide x

Also Published As

Publication number Publication date
BRPI0908496A2 (en) 2019-01-15
JP2011512417A (en) 2011-04-21
WO2009105669A3 (en) 2009-12-17
CN101951925A (en) 2011-01-19
WO2009105669A2 (en) 2009-08-27

Similar Documents

Publication Publication Date Title
IL207641A0 (en) Compositions comprising nucleic acids encoding vegf antagonists for use in treating ocular disease
IL254498B (en) Peptidomimetic macrocycle composition for use in treating disease
IL217540A (en) Oral composition for use in oral disinfection or in treating an oral disease
IL229059A (en) Pcsk9 antagonists
HK1207576A1 (en) Vla-1 antagonist for use in treating stroke vla-1
PL2468290T3 (en) Activin-ActRII Antagonists for use in treating anemia
IL207892A0 (en) Agent for treating disease
HK1151533A1 (en) Agent for treating disease
ZA201007215B (en) Agent for treating disease
PL2023945T3 (en) Composition for improving eye health
EP2452668A4 (en) Emulsified composition
PL2346356T3 (en) Liquid high-fat protein composition
LT2315773T (en) Polypeptides, polynucleotides and compositions for use in the treatment of latent tubeculosis
ZA201104062B (en) Compositions and methods for controlling disease in animals
EP2350042A4 (en) Novel thiophene compounds for use in theraphy
GB0921241D0 (en) Protein formulation
HK1154797A1 (en) Composition for treating disease
EP2262365A4 (en) Use of '-thio-2'-deoxynucleosides as anri orthopoxvirus agents
EP2337571A4 (en) Methods for determining the bioactivity of tgf-beta in a composition
EP2320931A4 (en) Compositions comprising mg29 nucleic acids, polypeptides and associated methods of use
EP2354223A4 (en) Nucleic acid drug for treating allergic disease
PL384259A1 (en) Pharmaceutical composition for treating skin-diseases
IL190579A (en) Latin game
HK1172547A1 (en) Activin-actrii antagonists for use in treating anemia -actrii
GB0910378D0 (en) Oil compositions for use in therapy